MD SB435

Retailers may only sell medetomidine or xylazine products to purchasers who provide proof of intended institutional, veterinary, or scientific use, and all purchasers must be at least 21 years old.

Retailers must maintain records of all sales, including copies of purchaser identification and documentation of intended use.

Civil penalties for violations are up to $3,000 for a first offense and up to $6,500 for each subsequent violation.

All collected civil penalties will be deposited into the Maryland Substance Abuse Fund.

The Maryland Department of Health is required to adopt regulations to implement the law, which takes effect October 1, 2026.